Botox maker Allergan confirmed Thursday that it was in early talks to combine with drug giant Pfizer Inc. in a deal that, if completed, would cap a remarkable spree of mergers this year that’s roiling the healthcare industry.
Allergan, a Dublin, Ireland-based firm with sizable operations in Irvine, said in a statement that it was approached by Pfizer and the discussions were “friendly,” but cautioned there was “no certainty” the talks would lead to a merger.
Allergan also declined comment on any possible terms of a deal. Allergan had a total stock-market value of $113 billion as of Wednesday’s close, so a Pfizer acquisition likelywould have a price tag well above that figure.
That would be the biggest deal of a year in which companies throughout the healthcare industry have joined forces to reposition themselves as various market and government forces, notably the Affordable Care Act, have changed the growth outlook for the firms’ revenues and profits.
Full content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI